Psychobiological aspects of somatization syndromes: Contributions of inflammatory cytokines and neopterin

Psychiatry Research

Volumn 195, Issue 1-2, 2012, Pages 60-65

  Euteneuer, Frank ^a   Schwarz, Markus J ^b   Hennings, Anika ^a   Riemer, Sabine ^a   Stapf, Theresa ^b   Selberdinger, Verena ^b   Rief, Winfried ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Interleukin 1 receptor antagonist; Interleukin 6; Screening for Somatoform Symptoms self rating scale 7; Somatoform symptoms; SOMS 7; Tumor necrosis factor alpha

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; NEOPTERIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PSYCHOBIOLOGY; SOMATIZATION; SPINAL CORD DORSAL HORN; SYMPATHETIC TONE;

ADULT; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPTERIN; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; SOMATOFORM DISORDERS; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 84860416490     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2011.07.032     Document Type: Article

References (59)

1. Barsky A.J., Borus J.F. Functional somatic syndromes. Annals of Internal Medicine 1999, 130:910-921.
2. Barsky A.J., Goodson J.D., Lane R.S., Cleary P.D. The amplification of somatic symptoms. Psychosomatic Medicine 1988, 50:510-519.
3. Beck A.T., Brown G., Steer R.A. Beck Depression Inventory II Manual 1996, The Psychological Corporation, San Antonio, TX.
4. Besedovsky H., del Rey A. Central and peripheral cytokines mediate immune-brain connectivity. Neurochemical Research 2011, 36:1-6.
5. Bleichhardt G., Timmer B., Rief W. Cognitive-behavioural therapy for patients with multiple somatoform symptoms - a randomised controlled trial in tertiary care. Journal of Psychosomatic Research 2004, 56:449-454.
6. Broderick G., Fuite J., Kreitz A., Vernon S.D., Klimas N., Fletcher M.A. A formal analysis of cytokine networks in chronic fatigue syndrome. Brain, Behavior, and Immunity 2011, 24:1209-1217.
7. Browning M., Fletcher P., Sharpe M. Can neuroimaging help us to understand and classify somatoform disorders? A systematic and critical review. Psychosomatic Medicine 2011, 73:173-184.
8. Capuron L., Schroecksnadel S., Féart C., Aubert A., Higueret D., Barberger-Gateau P., Layé S., Fuchs D. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biological Psychiatry 2011, 70(2):175-182.
9. Dantzer R. Cytokine-induced sickness behavior: where do we stand?. Brain, Behavior, and Immunity 2001, 15:7-24.
10. Dantzer R. Somatization: a psychoneuroimmune perspective. Psychoneuroendocrinology 2005, 30:947-952.
11. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience 2008, 9:46-56.
12. Derogatis L.R. SCL-90-R: Administration, Scoring and Procedures Manual 1994, National Computer Systems, Inc., Minneapolis, MN.
13. Dimsdale J.E., Creed F. The proposed diagnosis of somatic symptom disorders in DSM-V to replace somatoform disorders in DSM-IV-a preliminary report. Journal of Psychosomatic Research 2009, 66:473-476.
14. Dimsdale J.E., Dantzer R. A biological substrate for somatoform disorders: importance of pathophysiology. Psychosomatic Medicine 2007, 69:850-854.
15. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctot K.L. A meta-analysis of cytokines in major depression. Biological Psychiatry 2010, 67:446-457.
16. Escobar J.I., Rubio-Stipec M., Canino G., Karno M. Somatic symptom index (SSI): a new and abridged somatization construct: Prevalence and epidemiological correlates in two large community samples. The Journal of Nervous and Mental Disease 1989, 177:140-146.
17. Fuchs D., Hausen A., Reibnegger G., Werner E.R., Dierich M.P., Wachter H. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunology Today 1988, 9:150-155.
18. Fuchs D., Avanzas P., Arroyo-Espliguero R., Jenny M., Consuegra-Sanchez L., Kaski J. The role of neopterin in atherogenesis and cardiovascular risk assessment. Current Medicinal Chemistry 2009, 16:4644-4653.
19. Gaab J., Rohleder N., Heitz V., Engert V., Schad T., Schürmeyer T.H., Ehlert U. Stress-induced changes in lps-induced pro-inflammatory cytokine production in chronic fatigue syndrome. Psychoneuroendocrinology 2005, 30:188-198.
20. Gál E.M., Sherman A.D. L-kynurenine its synthesis and possible regulatory function in brain. Neurochemical Research 1980, 5:223-239.
21. Grammer T.B., Fuchs D., Boehm B.O., Winkelmann B.R., Maerz W. Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography in the Ludwigshafen risk and cardiovascular health study. Clinical Chemistry 2009, 55:1135-1146.
22. Hautzinger M., Kühner C., Keller F. Das Beck Depressionsinventar II. Deutsche Bearbeitung und Handbuch zum BDI II 2006, Harcourt Test Services, Frankfurt.
23. Hayaishi O. Properties and function of indoleamine 2,3-dioxygenase. Journal of Biochemistry 1976, 79:13-21.
24. Hiller W., Rief W., Fichter M.M. Further evidence for a broader concept of somatization disorder using the somatic symptom index. Psychosomatics 1995, 36:285-294.
25. Hiller W., Fichter M.M., Rief W. A controlled treatment study of somatoform disorders including analysis of healthcare utilization and cost-effectiveness. Journal of Psychosomatic Research 2003, 54:369-380.
26. Howren M.B., Lamkin D.M., Suls J. Associations of depression with c-reactive protein, il-1, and il-6: A meta-analysis. Psychosomatic Medicine 2009, 71:171-186.
27. Huber C., Batchelor J.R., Fuchs D., Hausen A., Lang A., Niederwieser D., Reibnegger G., Swetly P., Troppmair J., Wachter H. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. The Journal of Experimental Medicine 1984, 160:310-316.
28. Kirmayer L.J., Sartorius N. Cultural models and somatic syndromes. Psychosomatic Medicine 2007, 69:832-840.
29. Kroenke K., Spitzer R.L., deGruy F.V., Hahn S.R., Linzer M., Williams J.B.W., Brody D., Davies M. Multisomatoform disorder: an alternative to undifferentiated somatoform disorder for the somatizing patient in primary care. Archives of General Psychiatry 1997, 54:352-358.
30. Lekander M., Elofsson S., Neve I.M., Hansson L.O., Unden A.L. Self-rated health is related to levels of circulating cytokines. Psychosomatic Medicine 2004, 66:559-563.
31. Liebregts T., Adam B., Bredack C., Roeth A., Heinzel S., Lester S., Downie-Doyle S., Smith E., Drew P., Talley N.J., Holtmann G. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007, 132:913-920.
32. Lynch D.J., McGrady A., Nagel R., Zsembik C. Somatization in family practice: comparing 5 methods of classification. Journal of Clinical Psychiatry (Family Care Companion) 1999, 1(3):85-89.
33. Maes M. Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. Current Opinion in Psychiatry 2009, 22:75-83.
34. Maes M., Meltzer H.Y., Scharpé S., Cooreman W., Uyttenbroeck W., Suy E., Vandervorst C., Calabrese J., Raus J., Cosyns P. Psychomotor retardation, anorexia, weight loss, sleep disturbances, and loss of energy: psychopathological correlates of hyperhaptoglobinemia during major depression. Psychiatry Research 1993, 47:229-241.
35. Maes M., Yirmyia R., Noraberg J., Brene S., Hibbeln J., Perini G., Kubera M., Bob P., Lerer B., Maj M. The inflammatory & neurodegenerative (i&nd) hypothesis of depression: leads for future research and new drug developments in depression. Metabolic Brain Disease 2009, 24:27-53.
36. Nirkko O., Lauroma M., Siltanen P., Tuominen H., Vanhala K. Psychological risk factors related to coronary heart disease. Prospective studies among policemen in Helsinki. Acta Medica Scandinavica 1982, 211:137-146.
37. Oxenkrug G.F. Genetic and hormonal regulation of tryptophan-kynurenine metabolism. Annals of the New York Academy of Sciences 2007, 1122:35-49.
38. Oxenkrug G.F. Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40years later. Israel Journal of Psychiatry and Related Sciences 2010, 47:56-63.
39. Patarca R. Cytokines and chronic fatigue syndrome. Annals of the New York Academy of Sciences 2001, 933:185-200.
40. Reichenberg A., Yirmiya R., Schuld A., Kraus T., Haack M., Morag A., Pollmacher T. Cytokine-associated emotional and cognitive disturbances in humans. Archives of General Psychiatry 2001, 58:445-452.
41. Rief W., Barsky A.J. Psychobiological perspectives on somatoform disorders. Psychoneuroendocrinology 2005, 30:996-1002.
42. Rief W., Hiller W. Toward empirically based criteria for the classification of somatoform disorders. Journal of Psychosomatic Research 1999, 46:507-518.
43. Rief W., Hiller W. A new approach to the assessment of the treatment effects of somatoform disorders. Psychosomatics 2003, 44:492-498.
44. Rief W., Heuser J., Mayrhuber E.V.A., Stelzer I., Hiller W., Fichter M.M. The classification of multiple somatoform symptoms. The Journal of Nervous and Mental Disease 1996, 184:680-687.
45. Rief W., Pilger F., Ihle D., Bosmans E., Egyed B., Maes M. Immunological differences between patients with major depression and somatization syndrome. Psychiatry Research 2001, 105:165-174.
46. Rief W., Pilger F., Ihle D., Verkerk R., Scharpe S., Maes M. Psychobiological aspects of somatoform disorders: contributions of monoaminergic transmitter systems. Neuropsychobiology 2004, 49:24-29.
47. Rief W., Hennings A., Riemer S., Euteneuer F. Psychobiological differences between depression and somatization. Journal of Psychosomatic Research 2010, 68:495-502.
48. Riemer S., Maes M., Christophe A., Rief W. Lowered [omega]-3 pufas are related to major depression, but not to somatization syndrome. Journal of Affective Disorders 2010, 123:173-180.
49. Robinson C.M., Hale P.T., Carlin J.M. The role of ifn-gamma and tnf-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. Journal of Interferon & Cytokine Research 2005, 25:20-30.
50. Stein D., Muller J. Cognitive-affective neuroscience of somatization disorder and functional somatic syndromes: reconceptualizing the triad of depression-anxiety-somatic symptoms. CNS Spectrums 2010, 13:379-384.
51. Tabachnick B.G., Fidell L.S. Using Multivariate Statistics 2001, Allyn and Bacon, Needham Heights, MA. 4th ed.
52. Treede I., Braun A., Jeliaskova P., Giese T., Fullekrug J., Griffiths G., Stremmel W., Ehehalt R. Tnf-alpha-induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells. BMC Gastroenterology 2009, 9:53.
53. Vikman K.S., Hill R.H., Backström E., Robertson B., Kristensson K. Interferon-[gamma] induces characteristics of central sensitization in spinal dorsal horn neurons in vitro. Pain 2003, 106:241-251.
54. Vikman K.S., Duggan A.W., Siddall P.J. Interferon-[gamma] induced disruption of gabaergic inhibition in the spinal dorsal horn in vivo. Pain 2007, 133:18-28.
55. Ward L.C. Comparison of factor structure models for the Beck Depression Inventory-II. Psychological Assessment 2006, 18:81-88.
56. Watkins L.R., Maier S.F. Immune regulation of central nervous system functions: from sickness responses to pathological pain. Journal of Internal Medicine 2005, 257:139-155.
57. Widner B., Ledochowski M., Fuchs D. Interferon gamma induced tryptophan degradation neuropsychiatric and immunological consequences. Current Drug Metabolism 2000, 1:193-204.
58. Wieseler-Frank J., Maier S.F., Watkins L.R. Central proinflammatory cytokines and pain enhancement. Neurosignals 2005, 14:166-174.
59. Wittchen H.U., Zaudig M., Fydrich T. Skid. Strukturiertes klinisches Interview für DSM-IV. Achse I und II. Handanweisung 1997, Hogrefe, Göttingen.